All In Biotech

Free tool

FAERS Monitor: Nesacaine-Mpf

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 009435 or its brand name (Nesacaine-Mpf, Chloroprocaine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

34

Serious

20

59% of reports

Hospitalization

9

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective7
  • hypotension3
  • product label confusion3
  • anaesthetic complication2
  • areflexia2
  • arthralgia2
  • back pain2
  • bradycardia2
  • drug dose omission2
  • dyspnoea2
  • headache2
  • hypoaesthesia2
  • intentional product use issue2
  • intervertebral disc protrusion2
  • medication error2

Reports by year received

View as table
YearReports
20052
20062
20101
20112
20122
20133
20143
20151
20161
20173
20181
20191
20204
20214
20221
20233

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,125 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
areflexia2463.8120.8519
anaesthetic complication2461.1120.1515
product label confusionSignal3318.6108.1659
intervertebral disc protrusion256.614.861
bradycardia223.36.123
medication error222.35.822
intentional product use issue214.13.713
hypotensionSignal39.33.115
hypoaesthesia28.32.27
drug dose omission27.52.06
back pain25.31.43
drug ineffectiveSignal73.31.710
arthralgia23.00.81
dyspnoea22.20.60
headache22.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.